1887

Abstract

Chimeric 101F (ch101F) is a mouse–human chimeric anti-human respiratory syncytial virus (HRSV) neutralizing antibody that recognizes residues within antigenic site IV, V, VI of the fusion (F) glycoprotein. The binding of ch101F to a series of peptides overlapping aa 422–438 spanning antigenic site IV, V, VI was analysed. Residues 423–436 comprise the minimal peptide sequence for ch101F binding. Substitution analysis revealed that R429 and K433 are critical for ch101F binding, whilst K427 makes a minor contribution. Binding of ch101F to a series of single mutations at positions 427, 429 and 433 in the F protein expressed recombinantly on the cell surface confirmed the peptide results. Sequence analysis of viruses selected for resistance to neutralization by ch101F indicated that a single change (K433T) in the F protein allowed ch101F escape. The results confirm that ch101F and palivizumab have different epitope specificity and define key residues for ch101F recognition.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.82753-0
2007-10-01
2019-11-12
Loading full text...

Full text loading...

/deliver/fulltext/jgv/88/10/2719.html?itemId=/content/journal/jgv/10.1099/vir.0.82753-0&mimeType=html&fmt=ahah

References

  1. Anderson, L. J., Bingham, P. & Hierholzer, J. C. ( 1988; ). Neutralization of respiratory syncytial virus by individual and mixtures F and G protein monoclonal antibodies. J Virol 62, 4232–4238.
    [Google Scholar]
  2. Arbiza, J., Taylor, G., Lopez, J. A., Furze, J., Wyld, S., Whyte, P., Stott, E. J., Wertz, G., Sullender, W. & other authors ( 1992; ). Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. J Gen Virol 73, 2225–2234.[CrossRef]
    [Google Scholar]
  3. Beeler, J. A. & van Wyke Coelingh, K. ( 1989; ). Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol 63, 2941–2950.
    [Google Scholar]
  4. Bourgeois, C., Corvaisier, C., Bour, J. B., Kohli, E. & Pothier, P. ( 1991; ). Use of synthetic peptides to locate neutralizing antigenic domains on the fusion protein of respiratory syncytial virus. J Gen Virol 72, 1051–1058.[CrossRef]
    [Google Scholar]
  5. Branigan, P. J., Liu, C., Day, N. D., Gutshall, L. L., Sarisky, R. T. & Del Vecchio, A. M. ( 2005; ). Use of a novel cell-based fusion reporter assay to explore the host range of human respiratory syncytial virus F protein. Virol J 2, 54 [CrossRef]
    [Google Scholar]
  6. Crowe, J. E., Firestone, C. Y., Crim, R., Beeler, J. A., Coelingh, K. L., Barbas, C. F., Burton, D. R., Chanock, R. M. & Murphy, B. R. ( 1998; ). Monoclonal antibody-resistant mutants selected with a respiratory syncytial virus-neutralizing human antibody fab fragment (Fab 19) define a unique epitope on the fusion (F) glycoprotein. Virology 252, 373–375.[CrossRef]
    [Google Scholar]
  7. Day, N. D., Branigan, P. J., Liu, C., Gutshall, L. L., Luo, J., Melero, J. A., Sarisky, R. T. & Del Vecchio, A. M. ( 2006; ). Contribution of cysteine residues in the extracellular domain of the F protein of human respiratory syncytial virus to its function. Virol J 3, 34 [CrossRef]
    [Google Scholar]
  8. DeVincenzo, J. P., Hall, C. B., Kimberlin, D. W., Sanchez, P. J., Rodriguez, W. J., Jantausch, B. A., Corey, L., Kahn, J. S., Englund, J. A. & other authors ( 2004; ). Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. J Infect Dis 190, 975–978.[CrossRef]
    [Google Scholar]
  9. Dowell, S. F., Anderson, L. J., Gary, H. E., Erdman, D. D., Jr, Plouffe, J. F., File, T. M., Marston, B. J., Jr & Breiman, R. F. ( 1996; ). Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J Infect Dis 174, 456–462.[CrossRef]
    [Google Scholar]
  10. Ebbert, J. O. & Limper, A. H. ( 2005; ). Respiratory syncytial virus pneumonitis in immunocompromised adults: clinical features and outcome. Respiration 72, 263–269.[CrossRef]
    [Google Scholar]
  11. Feltes, T. F., Cabalka, A. K., Meissner, H. C., Piaza, F. M., Carlin, D. A., Top, F. H., Connor, E. M., Jr & Sondheimer, H. M. ( 2003; ). Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 143, 532–540.[CrossRef]
    [Google Scholar]
  12. Garcia-Barreno, B., Palomo, C., Penas, C., Delgado, T., Perez-Brena, P. & Melero, J. A. ( 1989; ). Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins. J Virol 63, 925–932.
    [Google Scholar]
  13. Han, L. L., Alexander, J. P. & Anderson, L. J. ( 1999; ). Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. J Infect Dis 179, 25–30.[CrossRef]
    [Google Scholar]
  14. Huang, Y. T., Collins, P. L. & Wertz, G. W. ( 1985; ). Characterization of the 10 proteins of human respiratory syncytial virus: identification of a fourth envelope-associated protein. Virus Res 2, 157–173.[CrossRef]
    [Google Scholar]
  15. Johnson, S., Oliver, C., Prince, G. A., Hemming, V. G., Pfarr, D. S., Wang, S. C., Dormitzer, M., O'Grady, J., Koenig, S. & other authors ( 1997; ). Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 176, 1215–1224.[CrossRef]
    [Google Scholar]
  16. Kruszynski, M., Stowell, N., Das, A., Seideman, J., Tsui, P., Brigham-Burke, M., Nemeth, J. F., Sweet, R. & Heavner, G. A. ( 2006; ). Synthesis and biological characterization of human monocyte chemoattractant protein 1 (MCP-1) and its analogs. J Pept Sci 12, 25–32.[CrossRef]
    [Google Scholar]
  17. Lopez, J. A., Bustos, R., Orvell, C., Berois, M., Arbiza, J., Garcia-Barreno, B. & Melero, J. A. ( 1998; ). Antigenic structure of human respiratory syncytial virus fusion glycoprotein. J Virol 72, 6922–6928.
    [Google Scholar]
  18. Machado, C. M., Vilas Boas, L. S., Mendes, A. V. A., Santos, M. F. M., da Rocha, I. F., Sturaro, D., Dulley, F. L. & Pannuti, C. S. ( 2003; ). Low mortality rates related to respiratory virus infections after bone marrow transplantation. Bone Marrow Transplant 31, 695–700.[CrossRef]
    [Google Scholar]
  19. Martin-Gallardo, A., Fien, K. A., Hu, B. T., Farley, J. F., Seid, R., Collins, P. L., Hildreth, S. W. & Paradiso, P. R. ( 1991; ). Expression of the F glycoprotein gene from human respiratory syncytial virus in Escherichia coli: mapping of a fusion inhibiting epitope. Virology 184, 428–432.[CrossRef]
    [Google Scholar]
  20. Shay, D. K., Holman, R. C., Newman, R. D., Liu, L. L., Stoud, J. W. & Anderson, L. J. ( 1999; ). Bronchiolitis-associated hospitalizations among US children, 1980–1996. JAMA 282, 1440–1446.[CrossRef]
    [Google Scholar]
  21. Shay, D. K., Holman, R. C., Roosevelt, G. E., Clarke, M. J. & Anderson, L. J. ( 2001; ). Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979–1997. J Infect Dis 183, 16–22.[CrossRef]
    [Google Scholar]
  22. Stensballe, L. G., Devasundaram, J. K. & Simoes, E. A. ( 2003; ). Respiratory syncytial virus epidemics: the ups and downs of a seasonal virus. Pediatr Infect Dis J 22 (Suppl.), S21–S32.
    [Google Scholar]
  23. Taylor, G., Stott, E. J., Bew, M., Fernie, B. F., Cote, P. J., Collins, A. P., Hughes, M. & Jebbet, J. ( 1984; ). Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunology 52, 137–142.
    [Google Scholar]
  24. Taylor, G., Stott, E. J., Furze, J., Ford, J. & Sopp, P. ( 1992; ). Protective epitopes on the fusion protein of respiratory syncytial virus recognized by murine and bovine monoclonal antibodies. J Gen Virol 73, 2217–2223.[CrossRef]
    [Google Scholar]
  25. Trudel, M., Nadon, F., Seguin, C., Dionne, G. & Lacroix, M. ( 1987; ). Identification of a synthetic peptide as part of a major neutralization epitope of respiratory syncytial virus. J Gen Virol 68, 2273–2280.[CrossRef]
    [Google Scholar]
  26. Ventre, K. & Randolph, A. ( 2004; ). Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev 4, CD000181
    [Google Scholar]
  27. Whimbey, E. & Ghosh, S. ( 2000; ). Respiratory syncytial virus infections in immunocompromised adults. Curr Clin Top Infect Dis 20, 232–255.
    [Google Scholar]
  28. Wu, H., Pfarr, D. S., Tang, Y., An, L. L., Patel, N. K., Watkins, J. D., Huse, W. D., Kiener, P. A. & Young, J. F. ( 2005; ). Ultra-potent antibodies against respiratoty syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol 350, 126–144.[CrossRef]
    [Google Scholar]
  29. Wu, H., Pfarr, D. S., Johnson, S., Brewah, Y. A., Woods, R. M., Patel, N. K., White, W. I., Young, J. F. & Kiener, P. A. ( 2007; ). Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 368, 652–665.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.82753-0
Loading
/content/journal/jgv/10.1099/vir.0.82753-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error